Please login to the form below

Not currently logged in
Email:
Password:

Ablynx reaches third Alzheimer's milestone

Boehringer Ingelheim has made a €5m milestone payment to Ablynx following the continued development of its nanobody candidate

Boehringer Ingelheim has made a €5m milestone payment to Ablynx following the continued development of its nanobody candidate.

In January 2007, Boehringer and Ablynx announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's nanobodies against a single disease target.

The collaboration has a potential value of $265m in upfront and milestone payments and undisclosed royalties on product sales.

Boehringer is responsible for the development, manufacturing and commercialisation of any products resulting from the collaboration.

Dr Edwin Moses, chairman and chief executive of Ablynx, said: "We are delighted that Boehringer Ingelheim is making further progress with the nanobody lead candidate which has the potential to be a first-in-class therapy for Alzheimer's disease and we look forward to this product advancing into the clinic in 2012."

It is the second milestone payment that Ablynx has received as part of its Alzheimer's research collaboration with Boehringer.

30th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
foxandcat.online

some pressure is helpful but too much of the wrong sort quickly takes its toll. we help creatove agenices manage...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...